Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 24, 2021

Medical Research Network to expand geographic presence

Decentralised clinical trials company Medical Research Network (MRN) has completed a private investment round and is all set to expand its geographic presence further.

Decentralised clinical trials company Medical Research Network (MRN) has completed a private investment round and is all set to expand its geographic presence further.

The investment round includes a £3m working capital facility from Shawbrook Bank.

Medical Research Network’s growth is aimed at improving its operational reach. It already has operations in North America, Europe and Australasia.

Through further development of its research & development capabilities, the company also plans to increase its offerings.

Medical Research Network CEO Graham Wylie said: “Our aim has always been to make the clinical trials process as efficient as possible by allowing patients to take part from the comfort of their own home, workplace or school.

“Our HTS services through the current pandemic has not only allowed patients to have access to potential medications they wouldn’t normally be able to access, but we have been fundamental in rescuing multi-million dollar clinical trials that would have collapsed due to the lack of access to hospitals.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The company works with global pharma, biotech and CRO companies, specialising in conducting clinical trial visits in patient’s homes as well as supporting the sites with specialist nursing resources.

Shawbrook Bank Corporate Lending team for the North West region director Sarah Laverty said: “For Shawbrook, MRN represents an excellent opportunity for the bank to support a very well-regarded existing customer, with a proven model and historic success in a growing global market.

“They have proved the value of ‘decentralised clinical trials’ well before the Covid pandemic hit and the demand for this service has only increased since then.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU